Cardiff Oncology, Inc. (CRDF) Stock Score, Valuation & Financial Research
Cardiff Oncology, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 21/100.
Quick answer for CRDF
Cardiff Oncology, Inc. currently has a Wall Street Score of 21/100. The stored market price is $1.35. Its financial score is 20/100. Its valuation score is 0/100. The latest WSS change is -0.3 points. These figures are a research snapshot, not a buy or sell recommendation.
What Cardiff Oncology, Inc. does
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated
CRDF financial snapshot
- Wall Street Score:
- 21/100
- Current price:
- $1.35
- Market capitalization:
- $104.0M
- Revenue:
- $508K
- Net income:
- $-40.1M
- Free cash flow:
- $-38.0M
- Cash:
- $9.2M
- Total debt:
- $457K
- EPS:
- -0.60
- Financial score:
- 20/100
- Valuation score:
- 0/100
- Revenue score:
- 8/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $-38.0M, showing cash burn in the current stored period.
- The balance sheet shows $9.2M of cash versus $457K of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.3 points: CRDF decreased 0.3 points because Asset declined by 2.7 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 20/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CRDF
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.